Navigation Links
Sanofi US and POZEN Sign Exclusive License Agreement for the Commercialization of PA8140/PA32540 Tablets in the U.S.
Date:9/4/2013

BRIDGEWATER, N.J. and CHAPEL HILL, N.J., Sept. 4, 2013 /PRNewswire/ -- Sanofi US (NYSE: SNY) and POZEN Inc. (NASDAQ: POZN) announced the signing of an exclusive license agreement for the commercialization of POZEN's proprietary, investigational, coordinated-delivery tablets combining immediate-release omeprazole, a proton pump inhibitor (PPI), and enteric-coated (EC) aspirin in a single tablet ("PA"), PA8140 and PA32540. Under the terms of the agreement, Sanofi will have exclusive rights to commercialize all PA combinations that contain 325 mg or less of enteric-coated aspirin in the United States. POZEN will receive an upfront payment of $15MM and will be eligible for pre-commercial milestone payments of up to $20MM and other future milestone payments and royalties on product sales.

(Logo: http://photos.prnewswire.com/prnh/20110616/NY20158LOGO)

"Sanofi has a strong heritage and expertise in the cardiovascular space, with Lovenox, Plavix, and most recently Multaq, and the PA products are an important addition to our already strong CV portfolio," said Anne Whitaker, President, North America Pharmaceuticals at Sanofi US. "The PA products have the potential to be an effective solution for the millions of patients at risk for gastric ulcers from chronic aspirin use in the prevention of secondary cardiovascular disease. We look forward to bringing this therapy to patients and healthcare providers."

Sanofi US will have responsibility for all sales, marketing, ongoing manufacturing and future development for the licensed PA products in the U.S.  POZEN will retain responsibility for obtaining approval o
'/>"/>

SOURCE Sanofi US
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Sanofi Pasteurs Fluzone High-Dose Vaccine Significantly More Effective Than Standard Dose Fluzone Vaccine in Preventing Influenza in Adults 65 Years of Age and Older
2. Sanofi Pasteur Announces Shipment of First Lots of 2013-2014 Seasonal Influenza Vaccine in U.S.
3. Sanofi US and Joslin Diabetes Center Announce Results from Multicultural Outreach Pilot at American Diabetes Association Scientific Sessions
4. Sanofi Announces Positive Phase 3 Results for Investigational New Insulin U300
5. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
6. Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine
7. Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis
8. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
9. Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)
10. Tolero Pharmaceuticals announces Worldwide Agreement with Sanofi for the In-license of Alvocidib (Flavopiridol)
11. NextBio Announces Translational Medicine Partnership with Sanofi
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... HILL, N.C. , May 22, 2015 /PRNewswire/ ... be hosting its sixth Medical Affairs ... 12:30PM (EDT) via a virtual roundtable to discuss ... Research." Best Practices, Medical Affairs Consortium ... sharing insights about the key challenges they face. ...
(Date:5/22/2015)... Taskforce representing Canada,s living victims of ... the Minister and Health Canada have put into this program ... of the thalidomide survivors, and more than 70% of them ... annual adjustments for inflation. Certain of the thalidomide ... on the severity of their disability, tax free, with inflation ...
(Date:5/22/2015)... 22, 2015  Amgen (NASDAQ: AMGN ... termination of its participation in the co-development ... STO:AZN and NYSE: AZN ).  Brodalumab, ... for patients with moderate-to-severe plaque psoriasis, psoriatic ... based on events of suicidal ideation and ...
Breaking Medicine Technology:Best Practices Sixth Medical Affairs Consortium Roundtable to Focus on Health Economics & Outcomes Research 2Amgen to terminate participation in co-development and commercialization of brodalumab 2Amgen to terminate participation in co-development and commercialization of brodalumab 3Amgen to terminate participation in co-development and commercialization of brodalumab 4Amgen to terminate participation in co-development and commercialization of brodalumab 5
... MISSISSAUGA, Ontario, March 29, 2011 GlaxoSmithKline (GSK) and ... (TSX: VRX) announced today that the European Commission has ... (add-on) treatment of partial onset seizures (a form of ... in one side of the brain), with or without ...
... Metabolic Solutions Development Company (MSDC), a drug discovery ... treat metabolic diseases, announced today that it has ... company,s second drug candidate for the treatment of ... and placebo-controlled clinical trial will involve approximately 125 ...
Cached Medicine Technology:GSK and Valeant Receive European Authorisation for Trobalt (retigabine) 2GSK and Valeant Receive European Authorisation for Trobalt (retigabine) 3GSK and Valeant Receive European Authorisation for Trobalt (retigabine) 4GSK and Valeant Receive European Authorisation for Trobalt (retigabine) 5Metabolic Solutions Development Company Launches Phase 2a Trial of Its Second Compound to Treat Type 2 Diabetes 2
(Date:5/25/2015)... NY (PRWEB) May 26, 2015 ... Anne King as a 2015-2016 inductee into ... is recognized with this prestigious distinction for leadership in ... exclusively for professional women, boasting more than 700,000 members ... pleased to welcome Anne into this exceptional group of ...
(Date:5/25/2015)... City, NY (PRWEB) May 26, 2015 ... honors Laquanis Hooker as a 2015-2016 inductee into its ... recognized with this prestigious distinction for leadership in dentistry. ... professional women, boasting more than 700,000 members and over ... welcome Laquanis into this exceptional group of professional women,” ...
(Date:5/25/2015)... (PRWEB) May 26, 2015 ... honors Dr. Heather Stanley-Christian as a ... Year Circle. She is recognized with this prestigious ... nation's leading networking organization exclusively for professional women, ... operating local chapters. , "I'm pleased to welcome ...
(Date:5/25/2015)... The National Association of Professional ... as a 2015-2016 inductee into its VIP Woman of ... distinction for leadership in biomedical engineering. NAPW is the ... more than 700,000 members and over 200 operating Local ... exceptional group of professional women," said NAPW President Star ...
(Date:5/25/2015)... 25, 2015 World Patent Marketing, a ... The Preventer, a home patent that aims to protect ... , "House fires cost the United States a total ... and Creative Director of World Patent Marketing . ... homes that have no alarmed protection. With the use ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Inducts Anne King, Operating Principal at Keller Williams, Into its VIP Professional Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Dr. Laquinas Hooked, D.D.S. of General Dentist, Into its VIP Professional Woman of the Year Circle 2Health News:NAPW Inducts Dr. Heather Stanley-Christian, Systems Chair/Maternal Fetal Medicine at Stroger Hospital, into Its VIP Professional Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Lisa Ferrara, Ph.D., CEO of OrthoKinetic Technologies, Into its VIP Professional Woman of the Year Circle 2Health News:Home Maintenance Causes House Fires? World Patent Marketing Introduces the Best Home Patent to Prevent Fire Accidents 2Health News:Home Maintenance Causes House Fires? World Patent Marketing Introduces the Best Home Patent to Prevent Fire Accidents 3
... Specialty Pharmaceutical Company with Greater Commercialization Capabilities, Expanded Portfolio of Pain ... King Extends Tender Offer Through December 19, 2008 ... N.J., Nov. 24 King Pharmaceuticals, Inc. (NYSE: KG ... that the two companies have signed a definitive merger agreement under ...
... Nov. 24 Transdel,Pharmaceuticals, Inc. (OTC Bulletin Board: ... and commercialization of non-invasive,topically targeted medications, today announced ... Company,s Board of Directors. , ... Swann, Inc., a consulting firm specializing in,marketing and ...
... resorts,are opening for the season, the Kelly Brush Foundation kicked ... the announcement of,over $20,000 in grants to ski racing clubs ... campaign to promote and improve ski racing safety. , ... of the most prestigious racing programs in,the nation including the ...
... DaVita Inc., a,leading provider of kidney care services ... kidney failure, continues to enhance DaVita.com to,make it ... well as a valuable,resource for patient education. DaVita.com/physicians ... people with chronic kidney disease and can,be found ...
... 24 ATS Medical, Inc.,(Nasdaq: ATSI ... and services, today announced that the first three ... completed by Dr. Allan,Stewart, Director, Aortic Surgery Program ... York ( http://www.ctsnet.org/home/allanstewart ) on November 17,and 18, ...
... ,Tis may be the season to be jolly but,tis ... lines that,barely move and public places stuffed with wheezing, sneezing ... makes keeping fit and healthy a bit of a challenge. ... find,Life123.com a comforting, mouse-click away. If you feel a ...
Cached Medicine News:Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 2Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 3Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 4Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 5Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 6Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 7Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 8Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 9Health News:Transdel Pharmaceuticals Appoints Mr. Lynn Swann, Pro-Football Hall of Famer, ABC Sports Broadcaster, and Former Chairman of the President's Council on Physical Fitness and Sports, to Board of Directors 2Health News:Transdel Pharmaceuticals Appoints Mr. Lynn Swann, Pro-Football Hall of Famer, ABC Sports Broadcaster, and Former Chairman of the President's Council on Physical Fitness and Sports, to Board of Directors 3Health News:Kelly Brush Foundation Awards Ski Racing Safety Grants 2Health News:DaVita.com Launches Physician Website 2Health News:DaVita.com Launches Physician Website 3Health News:ATS Medical Announces First Commercial Implants of the ATS 3f Aortic Bioprosthesis in the United States 2Health News:ATS Medical Announces First Commercial Implants of the ATS 3f Aortic Bioprosthesis in the United States 3Health News:Staying Healthy This Holiday Season Can be as Easy as Life123 2
Designed to determine the precise length of limbal incisions and proper alignment of closing sutures. Curved marking blade with 2 mm lines spaced 1 mm apart-measures up to 10 mm. Round knurled handle...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Medicine Products: